Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 18:9:41.
doi: 10.1186/s13045-016-0271-4.

L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia

Ki Sun Jung  1   2 , Su-Hee Cho  2 , Seok Jin Kim  1 , Young Hyeh Ko  3 , Eun-Suk Kang  4 , Won Seog Kim  5
Affiliations

L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia

Ki Sun Jung et al. J Hematol Oncol. .

Abstract

Aggressive nature killer cell leukemia (ANKL) is a mature NK-T cell lymphoma with worse prognosis, but optimal treatment is unclear. Therefore, we analyzed the efficacy of L-asparaginase-based regimens for ANKL patients. Twenty-one patients who received dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) or etoposide, ifosfamide, dexamethasone, and L-asparaginase (VIDL) chemotherapy at Samsung Medical Center were selected. The overall response rate for all patients was 33% (7/21); 38% (5/13) in SMILE and 40% (2/5) in VIDL, respectively. The median progression-free survival was 3.9 months (95% CI 0.0-8.1 months) and median overall survival was 7.0 months (95% CI 2.3-11.7 months). Treatment response (P = 0.001), hematopoietic stem cell transplantation (HSCT) (P = 0.007) and negative conversion of Epstein-Barr virus (EBV) DNA titer after treatment (P = 0.004) were significantly associated with survival. Thus, L-asparaginase-based regimens followed by allogeneic HSCT seem to improve the outcome for ANKL patients.

Keywords: ANKL; Allogeneic HSCT; L-asparaginase; Response; Survival.

PubMed Disclaimer

Figures

Fig 1
Fig 1
a Progression-free survival and b overall survival of 21 patients. c, d PFS and OS for patients who underwent HSCT and those who did not receive HSCT
See this image and copyright information in PMC

References

    1. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139:532–44. doi: 10.1111/j.1365-2141.2007.06835.x. - DOI - PubMed
    1. Song SY, Kim WS, Ko YH, Kim K, Lee MH, Park K. Aggressive natural killer cell leukemia: clinical features and treatment outcome. Haematologica. 2002;87:1343–5. - PubMed
    1. Ishida F, Ko YH, Kim WS, Suzumiya J, Isobe Y, Oshimi K, et al. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci. 2012;103:1079–83. doi: 10.1111/j.1349-7006.2012.02251.x. - DOI - PMC - PubMed
    1. Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18:763–70. doi: 10.1038/sj.leu.2403262. - DOI - PubMed
    1. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351–6. doi: 10.1002/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1. - DOI - PubMed

MeSH terms

LinkOut - more resources